Solway Pharm Health Limited 2170452 true 2023-10-01 2024-09-30 2024-09-30 The principal activity of the company is a dormant company Digita Accounts Production Advanced 6.30.9574.0 true R I Bell A J Barnes 2170452 2023-10-01 2024-09-30 2170452 2024-09-30 2170452 bus:OrdinaryShareClass1 2024-09-30 2170452 core:RetainedEarningsAccumulatedLosses 2024-09-30 2170452 core:ShareCapital 2024-09-30 2170452 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 2170452 bus:FRS102 2023-10-01 2024-09-30 2170452 bus:AuditExempt-NoAccountantsReport 2023-10-01 2024-09-30 2170452 bus:FullAccounts 2023-10-01 2024-09-30 2170452 bus:RegisteredOffice 2023-10-01 2024-09-30 2170452 bus:Director1 2023-10-01 2024-09-30 2170452 bus:Director3 2023-10-01 2024-09-30 2170452 bus:OrdinaryShareClass1 2023-10-01 2024-09-30 2170452 bus:EntityNoLongerTradingButTradedInPast 2023-10-01 2024-09-30 2170452 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 2170452 bus:Agent1 2023-10-01 2024-09-30 2170452 countries:AllCountries 2023-10-01 2024-09-30 2170452 2022-10-01 2023-09-30 2170452 2023-09-30 2170452 bus:OrdinaryShareClass1 2023-09-30 2170452 core:RetainedEarningsAccumulatedLosses 2023-09-30 2170452 core:ShareCapital 2023-09-30 2170452 core:CurrentFinancialInstruments core:WithinOneYear 2023-09-30 iso4217:GBP xbrli:pure xbrli:shares

REGISTRAR OF COMPANIES

Registration number: 2170452

Solway Pharm Health Limited

Unaudited Financial Statements

30 September 2024

image-name

 

Solway Pharm Health Limited

Contents

Accountants' Report

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Solway Pharm Health Limited
for the Year Ended 30 September 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Solway Pharm Health Limited for the year ended 30 September 2024 as set out on pages 2 to 4 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Solway Pharm Health Limited, as a body, in accordance with the terms of our engagement letter dated 9 December 2022. Our work has been undertaken solely to prepare for your approval the accounts of Solway Pharm Health Limited and state those matters that we have agreed to state to the Board of Directors of Solway Pharm Health Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Solway Pharm Health Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Solway Pharm Health Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and results of Solway Pharm Health Limited. You consider that Solway Pharm Health Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Solway Pharm Health Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.



Dodd & Co Audit Limited
Chartered Accountants
FIFTEEN Rosehill
Montgomery Way
Rosehill Estate
CARLISLE
CA1 2RW

24 March 2025

 

Solway Pharm Health Limited

(Registration number: 2170452)
Balance Sheet as at 30 September 2024

Note

2024
£

2023
£

Current assets

 

Debtors

4

456

456

Cash at bank and in hand

 

388

388

 

844

844

Capital and reserves

 

Called up share capital

6

2,000

2,000

Profit and loss account

(1,156)

(1,156)

Total equity

 

844

844

For the financial year ending 30 September 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 24 March 2025 and signed on its behalf by:
 

.........................................

A J Barnes

Director

 

Solway Pharm Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Station Works
Station Road
Aspatria
Wigton
CA7 3JW
United Kingdom

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for the sale of goods or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Solway Pharm Health Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2024 (continued)

3

Staff numbers

The average number of persons employed by the company during the year, was 2 (2023 - 2).

4

Debtors

Current

2024
£

2023
£

Trade debtors

456

456

 

456

456

5

Cash and cash equivalents

2024
£

2023
£

Cash at bank

388

388

6

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

2,000

2,000

2,000

2,000